The present invention relates generally to a novel method for producing pharmaceutical compositions of cinacalcet or pharmaceutically acceptable salts thereof in substantially dry powder form,which is very suitable for direct compression and for providing improved features of dissolution and compressibility. The method includes providing a core composition mixture including cinacalcet with a particle size distribution -d(90) of less than 150 [mu]m and a diluent wherein the core composition has a...

3-[3-(Trifluoromethyl)phenyl]propionaldehyde is a key intermediate for the preparation of cinacalcet hydrochloride. The present invention provides a novel process for the preparation of 3-[3-(trifluoromethyl)phenyl]propionaldehyde. The present invention also provides an improved process for preparation of cinacalcet hydrochloride in high yields. The present invention further provides a process for purification of cinacalcet hydrochloride.

3-[3-(Trifluoromethyl)phenyl]propionaldehyde is a key intermediate for the preparation of cinacalcet hydrochloride. The present invention provides a novel process for the preparation of 3-[3-(trifluoromethyl)phenyl]propionaldehyde. The present invention also provides an improved process for preparation of cinacalcet hydrochloride in high yields. The present invention further provides a process for purification of cinacalcet hydrochloride.

Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers s...

A new efficient method of producing Cinacalcet of formula I and its pharmaceutically acceptable salts, which consists in direct alkylation of (R)-(1-naphthyl)ethylamine of formula III with 3-[3-(trifluoromethyl)phenyl]propanol of formula II in presence of a catalyst in an inert organic solvent. Use of Cinacalcet of formula I prepared by the claimed method in preparation of pharmaceutically acceptable salts of Cinacalcet.